Locations:
Search IconSearch
November 28, 2025/Cancer

Management of Pregnancy-Associated Breast Cancer (Podcast)

Supporting patients during pregnancy and beyond

Pregnancy-associated breast cancer is defined as breast cancer diagnosed during pregnancy and after one year after pregnancy. This represents
roughly one in 3,000 pregnancies.

In a recent episode of Cleveland Clinic's Cancer Advances podcast, Erin Roesch, MD, Breast Medical Oncologist discussed:

  • Supporting patients through diagnosis, therapy and recovery
  • How a multidisciplinary team approach helps optimize treatment timing, ensures maternal and fetal safety
  • Managing side effects during pregnancy and chemotherapy
  • Addressing breast feeding during and after treatment

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Click the podcast player above to listen to the episode now.

Podcast excerpt:

Podcast host Dr. Shepard: I'm guessing that managing the complexity of having a breast cancer, coupled with pregnancy, must take a big team. We're going to talk about multidisciplinary care. What does that look like?

Dr. Roesch: Multidisciplinary are includes multiple team members - medical oncologists, breast surgeons, radiation oncologists, genetic counselors, social workers, psychologists, obstetricians, gynecologists and sometimes reproductive providers.

Dr. Shepard: Are there things over time we've learned to do really well?
Where do we need to make improvements?

Dr. Roesch: In terms of some of the psychosocial aspects, we're striving to make improvements and gain a better understanding of the needs of this
population beyond chemotherapy, radiation, and surgery.

It's about having a better understanding of this patient population. Many of these patients may be interested in future pregnancies, so engaging
reproductive endocrinology early on to discuss oncogertility, providing
access to psychologists and social workers, so they're aware that they
have a full team of support. That's an area where continuous improvement
could be made.

And in terms of advances in cancer treatment, how do those advances impact
these patients, whether it's in the systemic therapy realm or in surgical
techniques. There's a lot of room to grow.

Advertisement

Related Articles

Researcher with microscope
June 26, 2026/Cancer

Testosterone May Offer Anti-Tumor Activity in Glioblastoma

Research findings offer clues for improving disease outcomes in men

Male patient with doctor
June 17, 2026/Cancer/Patient Support

Overcoming Taboos: Helping Men with Cancer Restore Sexual Health

Creating a safe space for patients

Masked patient with physician
June 15, 2026/Cancer/Patient Support

Managing Infection Risk in the Era of Cell Therapy

Long-term immune effects reshape preventative strategies and timelines

Immune checkpoint inhibitor illustration
June 12, 2026/Cancer/News & Insight

Immunotherapy Appears to Reduce the Risk of Secondary Primary Cancers

Large-scale database also reveals potential for immunotherapy to protect against cancer

T53 mutation illustration
June 10, 2026/Cancer/News & Insight

TP53 Mutation Acquisition Timing Influences Prognosis in Myeloproliferative Neoplasms

Findings may help guide discussions around prognosis and allogeneic stem cell transplantation

Woman consoling another
June 5, 2026/Cancer/Blood Cancers

Equal Access to Modern Therapy May Help Eliminate Survival Differences in Multiple Myeloma

Research underscores the importance of access to timely diagnosis and treatment in this patient population.

Multiple myeloma cells
June 4, 2026/Cancer/Blood Cancers

Machine Learning Model Outperforms Standard Risk Tools for Multiple Myeloma

A Cleveland Clinic model combining clinical staging, genomics and AI predicts survival with 18% greater accuracy — and could help match patients to more effective treatments.

Dr. Kamath & colleagues in the lab
June 2, 2026/Cancer/News & Insight

Tissue Tumor Mutation Burden Outperforms Blood-Based Testing for Predicting Immunotherapy Response

Study serves as ‘cautionary tale’ for physicians tempted to rely on liquid biopsy results alone

Ad